Opinion|Videos|December 21, 2023
Update from the POLARIX Study on Pola-R-CHP in DLBCL
Medical oncologists discuss recent data from the POLARIX study investigating polatuzumab vedotin plus R-CHP in patients with diffuse large B-cell lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
2
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
5